HC Wainwright Has Bearish Forecast for COLL Q1 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at HC Wainwright cut their Q1 2025 earnings estimates for shares of Collegium Pharmaceutical in a research note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will post earnings of $1.20 per share for the quarter, down from their previous estimate of $1.29. HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q2 2025 earnings at $1.48 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

A number of other research analysts have also recently weighed in on COLL. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.96 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a market cap of $943.32 million, a price-to-earnings ratio of 12.91 and a beta of 0.99. The company’s 50-day moving average price is $30.51 and its 200 day moving average price is $32.52. Collegium Pharmaceutical has a 52 week low of $27.28 and a 52 week high of $42.29.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of Collegium Pharmaceutical by 19.5% in the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock worth $50,876,000 after purchasing an additional 289,335 shares during the period. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock valued at $47,603,000 after buying an additional 5,480 shares during the period. Geode Capital Management LLC lifted its position in Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after buying an additional 5,464 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after buying an additional 116,327 shares during the period.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 2,255 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now owns 124,421 shares of the company’s stock, valued at $3,732,630. This represents a 1.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 109,193 shares of company stock valued at $3,243,594. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.